keyword
MENU ▼
Read by QxMD icon Read
search

kidney transplant rejection management

keyword
https://www.readbyqxmd.com/read/27917694/outcomes-of-kidney-transplantation-in-alport-syndrome-compared-with-other-forms-of-renal-disease
#1
Yvelynne P Kelly, Anish Patil, Luke Wallis, Susan Murray, Saumitra Kant, Mohammed A Kaballo, Liam Casserly, Brendan Doyle, Anthony Dorman, Patrick O'Kelly, Peter J Conlon
INTRODUCTION: Alport syndrome is an inherited renal disease characterized by hematuria, renal failure, hearing loss and a lamellated glomerular basement membrane. Patients with Alport syndrome who undergo renal transplantation have been shown to have patient and graft survival rates similar to or better than those of patients with other renal diseases. METHODS: In this national case series, based in Beaumont Hospital Dublin, we studied the cohort of patients who underwent renal transplantation over the past 33 years, recorded prospectively in the Irish Renal Transplant Registry, and categorized them according to the presence or absence of Alport syndrome...
December 5, 2016: Renal Failure
https://www.readbyqxmd.com/read/27776143/defining-priorities-for-future-research-results-of-the-uk-kidney-transplant-priority-setting-partnership
#2
Simon R Knight, Leanne Metcalfe, Katriona O'Donoghue, Simon T Ball, Angela Beale, William Beale, Rachel Hilton, Keith Hodkinson, Graham W Lipkin, Fiona Loud, Lorna P Marson, Peter J Morris
BACKGROUND: It has been suggested that the research priorities of those funding and performing research in transplantation may differ from those of end service users such as patients, carers and healthcare professionals involved in day-to-day care. The Kidney Transplant Priority Setting Partnership (PSP) was established with the aim of involving all stakeholders in prioritising future research in the field. METHODS: The PSP methodology is as outlined by the James Lind Alliance...
2016: PloS One
https://www.readbyqxmd.com/read/27686224/profiling-risk-for-acute-rejection-in-kidney-transplantation-recipient-age-is-a-robust-risk-factor
#3
Abbas Rana, Bhamidipati Murthy, Zachery Pallister, Michael Kueht, Ronald Cotton, N Thao N Galvan, Whiston Etheridge, Hau Liu, John Goss, Christine O'Mahony
Careful management of immunosuppression is paramount to prevent acute rejection in kidney transplantation. We studied a cohort of 139,875 kidney transplant recipients from the Organ Procurement and Transplantation Network (OPTN) database between 2002 and 2013. We confirmed the analysis with a cohort of 35,277 who received thymoglobulin induction with tacrolimus maintenance, and a third cohort of 12,161 recipients who received basiliximab induction with tacrolimus maintenance. We performed multivariate logistic regression analyses on data from all three cohorts and identified independent risk factors for treated acute rejection at 1 year...
September 29, 2016: Journal of Nephrology
https://www.readbyqxmd.com/read/27643978/targeted-preemptive-therapy-according-to-perceived-risk-of-cmv-infection-after-kidney-transplantation
#4
Cahue Henrique Pinto, Helio Tedesco-Silva, Claudia Rosso Felipe, Alexandra Nicolau Ferreira, Marina Cristelli, Laila Almeida Viana, Wilson Aguiar, José Medina-Pestana
BACKGROUND: The identification of the best strategy to manage cytomegalovirus infection is hampered by uncertainties regarding the risk/benefit ratios of universal prophylaxis versus preemptive therapy, the impact of indirect cytomegalovirus effects and the associated costs. This study investigated the efficacy and safety of targeted preemptive therapy according to perceived risk of cytomegalovirus infection after kidney transplantation. METHODS: 144 adult kidney transplant recipients were enrolled in this 12-month study...
September 24, 2016: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27622599/high-dose-steroid-therapy-in-bk-viremia-adversely-affected-the-long-term-graft-function-after-kidney-transplantation
#5
H Kim, H Yu, C H Baek, D J Han, S-K Park
BACKGROUND: Although high-dose steroid therapy has been attempted for the management of clinically suspected allograft rejection, before testing for BK viral activity or acute cellular rejection accompanied by BKN, its long-term outcome remains unknown. We investigated the impact of high-dose steroids on BK viral activity and long-term graft outcomes in patients with BK viremia. METHODS: The study population comprised 144 kidney transplant recipients with BK viremia...
September 13, 2016: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/27578428/immunosuppressive-therapy-for-kidney-transplantation-in-adults-a-systematic-review-and-economic-model
#6
Tracey Jones-Hughes, Tristan Snowsill, Marcela Haasova, Helen Coelho, Louise Crathorne, Chris Cooper, Ruben Mujica-Mota, Jaime Peters, Jo Varley-Campbell, Nicola Huxley, Jason Moore, Matt Allwood, Jenny Lowe, Chris Hyde, Martin Hoyle, Mary Bond, Rob Anderson
BACKGROUND: End-stage renal disease is a long-term irreversible decline in kidney function requiring renal replacement therapy: kidney transplantation, haemodialysis or peritoneal dialysis. The preferred option is kidney transplantation, followed by immunosuppressive therapy (induction and maintenance therapy) to reduce the risk of kidney rejection and prolong graft survival. OBJECTIVES: To review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab (BAS) (Simulect(®), Novartis Pharmaceuticals UK Ltd) and rabbit anti-human thymocyte immunoglobulin (rATG) (Thymoglobulin(®), Sanofi) as induction therapy, and immediate-release tacrolimus (TAC) (Adoport(®), Sandoz; Capexion(®), Mylan; Modigraf(®), Astellas Pharma; Perixis(®), Accord Healthcare; Prograf(®), Astellas Pharma; Tacni(®), Teva; Vivadex(®), Dexcel Pharma), prolonged-release tacrolimus (Advagraf(®) Astellas Pharma), belatacept (BEL) (Nulojix(®), Bristol-Myers Squibb), mycophenolate mofetil (MMF) (Arzip(®), Zentiva; CellCept(®), Roche Products; Myfenax(®), Teva), mycophenolate sodium (MPS) (Myfortic(®), Novartis Pharmaceuticals UK Ltd), sirolimus (SRL) (Rapamune(®), Pfizer) and everolimus (EVL) (Certican(®), Novartis) as maintenance therapy in adult renal transplantation...
August 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27570751/impact-of-donor-source-on-the-outcome-of-live-donor-kidney-transplantation-a-single-center-experience
#7
Yasser Elsayed Matter, Ayman M Nagib, Omar E Lotfy, Ahmed Maher Alsayed, Ahmed F Donia, Ayman F Refaie, Ahmed I Akl, Mohamed Hamed Abbas, Mohammed M Abuelmagd, Hussein A Shaeashaa, Ahmed A Shokeir
BACKGROUND: Renal transplantation is the ideal method for management of end-stage renal disease. The use of living donors for renal transplantation was critical for early development in the field and preceded the use of cadaveric donors. Most donors are related genetically to the recipients, like a parent, a child, or a sibling of the recipient, but there are an increasing percentage of cases where donors are genetically unrelated like spouses, friends, or altruistic individuals. Donor shortages constitute the major barrier for kidney transplantation, and much effort has been made to increase the supply of living donors...
May 2016: Nephro-urology Monthly
https://www.readbyqxmd.com/read/27557331/immunosuppressive-therapy-for-kidney-transplantation-in-children-and-adolescents-systematic-review-and-economic-evaluation
#8
Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Louise Crathorne, Chris Cooper, Jo Varley-Campbell, Ruben Mujica-Mota, Helen Coelho, Nicola Huxley, Jenny Lowe, Jan Dudley, Stephen Marks, Chris Hyde, Mary Bond, Rob Anderson
BACKGROUND: End-stage renal disease is a long-term irreversible decline in kidney function requiring kidney transplantation, haemodialysis or peritoneal dialysis. The preferred option is kidney transplantation followed by induction and maintenance immunosuppressive therapy to reduce the risk of kidney rejection and prolong graft survival. OBJECTIVES: To systematically review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab (BAS) (Simulect,(®) Novartis Pharmaceuticals) and rabbit antihuman thymocyte immunoglobulin (Thymoglobuline,(®) Sanofi) as induction therapy and immediate-release tacrolimus [Adoport(®) (Sandoz); Capexion(®) (Mylan); Modigraf(®) (Astellas Pharma); Perixis(®) (Accord Healthcare); Prograf(®) (Astellas Pharma); Tacni(®) (Teva); Vivadex(®) (Dexcel Pharma)], prolonged-release tacrolimus (Advagraf,(®) Astellas Pharma); belatacept (BEL) (Nulojix,(®) Bristol-Myers Squibb), mycophenolate mofetil (MMF) [Arzip(®) (Zentiva), CellCept(®) (Roche Products), Myfenax(®) (Teva), generic MMF is manufactured by Accord Healthcare, Actavis, Arrow Pharmaceuticals, Dr Reddy's Laboratories, Mylan, Sandoz and Wockhardt], mycophenolate sodium, sirolimus (Rapamune,(®) Pfizer) and everolimus (Certican,(®) Novartis Pharmaceuticals) as maintenance therapy in children and adolescents undergoing renal transplantation...
August 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27534951/results-of-a-multicenter-prospective-clinical-study-in-japan-for-evaluating-efficacy-and-safety-of-desensitization-protocol-based-on-rituximab-in-abo-incompatible-kidney-transplantation
#9
Kota Takahashi, Kazuhide Saito, Shiro Takahara, Shohei Fuchinoue, Takashi Yagisawa, Atsushi Aikawa, Yoshihiko Watarai, Norio Yoshimura, Kazunari Tanabe, Kunio Morozumi, Motohide Shimazu
BACKGROUND: Deceased organ donations are rare in Japan, with most kidney transplants performed from a limited number of living donors. Researchers have thus developed highly successful ABO-incompatible transplantation procedures, emphasizing preoperative desensitization and postoperative immunosuppression. A recent open-label, single-arm, multicenter clinical study prospectively examined the efficacy and safety of rituximab/mycophenolate mofetil desensitization in ABO-incompatible kidney transplantation without splenectomy...
August 17, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27501275/kidney-intragraft-homing-of-de-novo-donor-specific-hla-antibodies-is-an-essential-step-of-antibody-mediated-damage-but-not-per-se-predictive-of-graft-loss
#10
A Nocera, A Tagliamacco, M Cioni, A Innocente, I Fontana, G Barbano, A Carrea, M Ramondetta, A Sementa, S Basso, G Quartuccio, C Klersy, M Bertocchi, E Verrina, G Garibotto, G M Ghiggeri, M Cardillo, P Comoli, F Ginevri
Donor-specific HLA antibody (DSA)-mediated graft injury is the major cause of kidney loss. Among DSA characteristics, graft homing has been suggested as an indicator of severe tissue damage. We analyzed the role of de novo DSA (dnDSA) graft homing on kidney transplantation outcome. Graft biopsy specimens and parallel sera from 48 nonsensitized pediatric kidney recipients were analyzed. Serum samples and eluates from graft biopsy specimens were tested for the presence of dnDSAs with flow bead technology. Intragraft dnDSAs (gDSAs) were never detected in the absence of serum dnDSAs (sDSAs), whereas in the presence of sDSAs, gDSAs were demonstrated in 72% of biopsy specimens...
August 8, 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/27479171/immunological-characteristics-of-renal-transplant-tolerance-in-humans
#11
REVIEW
Jingli Lu, Xiaojian Zhang
Establishing allograft tolerance is a highly desirable therapeutic goal in kidney transplantation, from which recipients would greatly benefit by withdrawing or minimizing immunosuppression. Identifying biomarkers in predicting tolerance or early diagnosing rejection is essential to direct personalized management. Recent findings have revealed that multiple populations of immune cells have involved in promoting long-term graft function or inducing rejection in renal transplant recipients. Thus, roles of immune cells add another level to predict the renal tolerant state; tailoring their functional and/or phenotypic characteristics would provide insights into mechanism involved in transplant tolerance that may aid in designing new therapies...
September 2016: Molecular Immunology
https://www.readbyqxmd.com/read/27415632/efficacy-and-safety-of-direct-acting-antivirals-in-kidney-transplant-recipients-with-chronic-hepatitis-c-virus-infection
#12
Ming V Lin, Meghan E Sise, Martha Pavlakis, Beth M Amundsen, Donald Chute, Anna E Rutherford, Raymond T Chung, Michael P Curry, Jasmine M Hanifi, Steve Gabardi, Anil Chandraker, Eliot C Heher, Nahel Elias, Leonardo V Riella
The prevalence of Hepatitis C Virus (HCV) infection is significantly higher in patients with end-stage renal disease compared to the general population and poses important clinical challenges in patients who undergo kidney transplantation. Historically, interferon-based treatment options have been limited by low rates of efficacy and significant side effects, including risk of precipitating rejection. Limited data exist on the use of all-oral, interferon-free direct-acting antiviral (DAA) therapies in kidney transplant recipients...
2016: PloS One
https://www.readbyqxmd.com/read/27348472/evidence-for-an-important-role-of-both-complement-binding-and-noncomplement-binding-donor-specific-antibodies-in-renal-transplantation
#13
Denis Viglietti, Carmen Lefaucheur, Denis Glotz
PURPOSE OF REVIEW: The review describes the current clinical relevance of circulating anti-human leukocyte antigen (anti-HLA) antibodies in kidney transplantation and discusses recent improvements in their characterization that provide new insights into the identification and management of important clinical outcomes. RECENT FINDINGS: Recent studies addressing the relationships between donor-specific anti-HLA antibody (HLA-DSA) properties (i.e., their strength, complement-binding capacity, and IgG subclass composition) and allograft injury and survival have highlighted their relevance in the prediction of antibody-mediated injury and allograft loss...
August 2016: Current Opinion in Organ Transplantation
https://www.readbyqxmd.com/read/27323293/stressors-and-coping-resources-of-australian-kidney-transplant-recipients-related-to-medication-taking-a-qualitative-study
#14
Jac Kee Low, Kimberley Crawford, Elizabeth Manias, Allison Williams
AIM: To understand the stressors related to life post-kidney transplantation, with a focus on medication adherence, and the coping resources people use to deal with these stressors. BACKGROUND: Although kidney transplantation offers enhanced quality and years of life for patients, the management of a kidney transplant post-surgery is a complex process. DESIGN: A descriptive exploratory study. METHOD: Participants were recruited from five kidney transplant units in Victoria, Australia...
June 20, 2016: Journal of Clinical Nursing
https://www.readbyqxmd.com/read/27267780/bk-virus-in-kidney-transplant-current-concepts-recent-advances-and-future-directions
#15
Rajeev Sharma, Stephanie Tzetzo, Sunil Patel, Mareena Zachariah, Sonakshi Sharma, Thomas Melendy
BK virus nephropathy is a challenging clinical problem in kidney transplant recipients with wide range of surveillance and management practices, based on individual experience. BK virus reactivation in kidney transplant recipients can result in BK virus nephropathy and graft loss. The most effective strategy for early diagnosis and treatment of BK virus nephropathy is regular monitoring for BK virus, currently achieved by quantification of viral DNA in blood by quantitative polymerase chain reaction. Immunosuppression reduction remains the mainstay of treatment; however, viral clearance is often followed by acute rejection, likely secondary to a delay between immune reconstitution and viral clearance...
August 2016: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/27264024/the-transplant-team-s-support-of-kidney-transplant-recipients-to-take-their-prescribed-medications-a-collective-responsibility
#16
Allison Williams, Jac Kee Low, Elizabeth Manias, Kimberley Crawford
AIMS AND OBJECTIVES: To obtain an understanding of how health professionals support the kidney transplant patient to take their medications as prescribed long term. BACKGROUND: Kidney transplantation requires stringent adherence to complex medication regimens to prevent graft rejection and to maintain general well-being. Medication nonadherence is common in kidney transplantation, emerging in the first few months post-transplantation, leading to poor patient outcomes...
August 2016: Journal of Clinical Nursing
https://www.readbyqxmd.com/read/27234746/clinical-outcomes-and-results-of-pathological-findings-of-1-year-protocol-biopsy-in-recipients-of-abo-incompatible-living-donor-kidney-transplantants
#17
T Yokoyama, O Konno, Y Kihara, Y Nakamura, H Iwamoto, S Kawachi
OBJECTIVES: ABO-incompatible kidney transplantation has increased the possibility of finding suitable living donors for patients with renal failure. However, there are inevitable immunological risks, including a high risk of early post-transplantation complications. The purpose of this study was to evaluate recipient outcomes following ABO-incompatible kidney transplantation. METHODS: Seventy-one patients who had undergone living-donor kidney transplantation (LDKT) at our center between January 2008 and December 2013 were divided into ABO-incompatible (ABOi; n = 21) and ABO-compatible (ABOc; n = 50) groups...
April 2016: Transplantation Proceedings
https://www.readbyqxmd.com/read/27227927/pretransplant-hepatitis-b-viral-infection-increases-risk-of-death-after-kidney-transplantation-a-multicenter-cohort-study-in-korea
#18
Jeonghwan Lee, Jang-Hee Cho, Jong Soo Lee, Dong-Won Ahn, Chan-Duck Kim, Curie Ahn, In Mok Jung, Duck Jong Han, Chun Soo Lim, Yon Su Kim, Young Hoon Kim, Jung Pyo Lee
Clinical outcomes in kidney transplant recipients (KTRs) with hepatitis B virus (HBV) have not been thoroughly evaluated. Here, we investigated recent posttransplant clinical outcomes of KTRs with HBV and compared them with KTRs with hepatitis C virus (HCV) and seronegative KTRs.Of 3855 KTRs from April 1999 to December 2011, we enrolled 3482 KTRs who had viral hepatitis serology data; the patients were followed up for 89.1 ± 54.1 months. The numbers of recipients with HBV and HCV were 160 (4.6%) and 55 (1...
May 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27225723/efficacy-of-combined-plasmapheresis-and-intravenous-immunoglobulin-therapy-in-kidney-transplant-patients-with-chronic-antibody-mediated-rejection
#19
Ebru Gok Oguz, Gulay Ulusal Okyay, Hadim Akoglu, Ozgur Merhametsiz, Tolga Yildirim, Basol Canbakan, Mehmet Deniz Ayli
INTRODUCTION: Antibody-mediated rejections (AMRs) are critical clinical issues encountered in short- and long-term follow-up of kidney transplant patients. Whereas plasmapheresis is a mainstay treatment option in acute AMR cases, there is a paucity of data regarding its efficacy in management of chronic AMR. This report describes our experience addressing this issue. MATERIALS AND METHODS: We retrospectively investigated the data of 7 kidney transplant patients diagnosed with chronic AMR who were on 5 sessions of plasmapheresis (1 to 2 volume exchanges with fresh frozen plasma) on alternate days and 200 mg/kg of intravenous immunoglobulin after each session of plasmapheresis...
May 2016: Iranian Journal of Kidney Diseases
https://www.readbyqxmd.com/read/27219240/simultaneous-scalp-skull-kidney-and-pancreas-transplant-from-a-single-donor
#20
Jesse C Selber, Edward I Chang, Mark W Clemens, Lilian Gaber, Matthew M Hanasono, Michael Klebuc, Roman J Skoracki, Todd Trask, Peirong Yu, A Osama Gaber
BACKGROUND: Vascularized composite allotransplantation is an emerging field, but the complications of lifelong immunosuppression limit indications. Vascularized composite allotransplantation in solid organ recipients represents a unique opportunity because immunosuppression has already been accepted. This report of a simultaneous scalp, skull, kidney, and pancreas transplant represents both the first skull-scalp transplant and combination of a vascularized composite allotransplantation with double organ transplantation...
June 2016: Plastic and Reconstructive Surgery
keyword
keyword
91201
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"